Previous 10 | Next 10 |
Agency Awards $19 Million Contract to Fund Research and Development Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to support research and development effort...
Hologic, Inc. ( NASDAQ: HOLX ) gained ~7% pre-market Tuesday as analysts issued favorable views on the COVID-19 test developer’s Q4 fiscal 2022 results that exceeded the company forecasts and the consensus. The company’s 2023 outlook which was in line w...
Hologic, Inc. (HOLX) Q4 2022 Earnings Conference Call October 31, 2022 04:30 PM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi ...
The shares of Hologic, Inc. ( NASDAQ: HOLX ) spiked in the post-market trading Monday after the healthcare device maker said its financial measures for Q4 fiscal 2022 exceeded expectations even as the topline slumped amid pressure on COVID-19 testing and Breast Health business...
Hologic press release ( NASDAQ: HOLX ): Q4 Non-GAAP EPS of $0.82 beats by $0.20 . Revenue of $953.3M (-27.8% Y/Y) beats by $91.62M . FY 2023 Guidance: Revenue expected between $3.7 - $3.9B vs. consensus of $3.87B; Non-GAAP EPS of $3.30 - $3.60 vs. consensus o...
– Revenue of $953 Million, GAAP Diluted EPS of $0.47, and Non-GAAP Diluted EPS of $0.82 All Exceed Expectations – – Global Organic Molecular Diagnostics Revenue Grows 17% in Constant Currency, ex-COVID-19 – – Fiscal 2023 Financial Guidance Anti...
Hologic ( NASDAQ: HOLX ) is scheduled to announce Q4 earnings results on Monday, October 31st, after market close. The consensus EPS Estimate is $0.62 (-61.5% Y/Y) and the consensus Revenue Estimate is $861.68M (-34.7% Y/Y). Over the last 2 years, HOLX has beaten EPS...
Summary Insulet Corporation has an interesting business model and management continues to grow the company's top line nicely. However, profits and cash flows have been showing signs of weakness and the stock looks very pricey at this time. Investors should be careful about thi...
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2022 on Monday, October 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Easter...
Tennis Legend Martina Navratilova Joins Hologic to Highlight Importance of Regular Screenings Hologic, Inc. Chairman, President and CEO Steve MacMillan will ring the Nasdaq opening bell today to mark the beginning of Breast Cancer Awareness Month. This is the 16 th t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...